TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30449509

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both LSG and LRYGB
Number of subjects: 20
Study: 30449647

Group type: EXPERIMENTAL
Intervention: Care coordinator services
Number of subjects: 2061
Study: 30449712

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 203

Group type: COMPARATOR
Intervention: PTSD Health Education (HE)
Number of subjects: 203
Study: 30450044

Group type: EXPERIMENTAL
Intervention: tDCS and cognitive intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30450355

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30450469

Group type: EXPERIMENTAL
Intervention: Proenkephalin A 119-159 (Penkid)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 583
Study: 30450553

Group type: EXPERIMENTAL
Intervention: Ventricular global longitudinal strain assessment
Number of subjects: 143
Study: 30450591

Group type: EXPERIMENTAL
Intervention: Aurora B kinase inhibitor BI 811283 in combination with cytarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytarabine alone
Number of subjects: 0
Study: 30451655

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg once weekly for 24 weeks
Number of subjects: 187
Study: 30451741

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rapamycin (RAPA)
Number of subjects: 0
Study: 30451764

Group type: EXPERIMENTAL
Intervention: Texture analysis of T2-weighted magnetic resonance images
Number of subjects: 114
Study: 30452076

Group type: EXPERIMENTAL
Intervention: Contour 3D annuloplasty ring
Number of subjects: 112
Study: 30452500

Group type: EXPERIMENTAL
Intervention: No ROP prior to hospital discharge
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: ROP treatment at 32 weeks' postmenstrual age
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: ROP treatment at 33 weeks' postmenstrual age
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: No ROP at hospital discharge for infants 27 to 33 weeks' gestational age
Number of subjects: 1257

Group type: COMPARATOR
Intervention: No ROP at hospital discharge for infants less than 27 weeks' gestational age
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Follow-up of infants without ROP by 37 weeks' postmenstrual age
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Larger birth weight and higher gestational age
Number of subjects: 1257
Study: 30452666

Group type: EXPERIMENTAL
Intervention: VSV-EBOV vaccine (single-dose regimen)
Number of subjects: 0
Study: 30452963

Group type: COMPARATOR
Intervention: Symptom duration < 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom duration ≥ 2 years
Number of subjects: 0
Study: 30454733

Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 567
Study: 30454753

Group type: EXPERIMENTAL
Intervention: Induction and maintenance immunosuppression
Number of subjects: 0
Study: 30454872

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy
Number of subjects: 0
Study: 30455089

Group type: EXPERIMENTAL
Intervention: Ideal care for women veterans as articulated by local health leaders
Number of subjects: 86
Study: 30455168

Group type: EXPERIMENTAL
Intervention: Teledialog Telerehabilitation Program
Number of subjects: 37
Study: 30455171

Group type: EXPERIMENTAL
Intervention: Tablet-based app for consent process
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard practice consent process
Number of subjects: 100
Study: 30455225

Group type: EXPERIMENTAL
Intervention: Molecular subsets characterized by translocations involving chimeric oncogenes
Number of subjects: 0
Study: 30455340

Group type: EXPERIMENTAL
Intervention: Marijuana exposure (COOH-THC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental marijuana use
Number of subjects: 0
Study: 30455404

Group type: EXPERIMENTAL
Intervention: Early OAC (0-4 days)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Late OAC (≥5 days or never started)
Number of subjects: 1355
Study: 30455722

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study: 30455964

Group type: EXPERIMENTAL
Intervention: mhGAP training of primary health care providers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no mhGAP training)
Number of subjects: 36
Study: 30456327

Group type: EXPERIMENTAL
Intervention: Daily Isoniazid with peer counseling
Number of subjects: 263

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 263
Study: 30457484

Group type: EXPERIMENTAL
Intervention: Virtual hepatic venous pressure gradient (HVPG)
Number of subjects: 102
Study: 30457897

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventana PD-L1 (SP263) assay
Number of subjects: 0
Study: 30458511

Group type: EXPERIMENTAL
Intervention: Synthesized images of animate and inanimate objects with matched curvilinear and rectilinear information, presented as texture patterns.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthesized images of animate and inanimate objects with no feedback given.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthesized images classified as animate.
Number of subjects: 0
Study: 30458747

Group type: EXPERIMENTAL
Intervention: Phasix™ Mesh
Number of subjects: 85
Study: 30459074

Group type: EXPERIMENTAL
Intervention: Higher flavonoids intake (fifth quintile)
Number of subjects: 17065

Group type: COMPARATOR
Intervention: Lowest quintile of flavonoids intake
Number of subjects: 17065
Study: 30459098

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study: 30459138

Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) group intervention led by mental health professionals (MHPs)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) group intervention led by paraprofessional home visitors
Number of subjects: 933

Group type: COMPARATOR
Intervention: Usual home visiting (HV) services
Number of subjects: 933
Study: 30459144

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Medical interventions
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Procedural interventions
Number of subjects: 1500
Study: 30459647

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Severe depression subgroup (HAMD-17 ≥ 25)
Number of subjects: 561
Study: 30459653

Group type: EXPERIMENTAL
Intervention: Community-Based Addiction Rehabilitation Electronic System
Number of subjects: 0
Study: 30460321

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30460495

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC) serum levels
Number of subjects: 2803
Study: 30460518

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg bid (octogenarians)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Apixaban 2.5 mg bid (octogenarians with appropriately reduced dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Younger patients (age < 70 years)
Number of subjects: 80
Study: 30460684

Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg and cyclophosphamide 300 mg/m² with low-dose dexamethasone
Number of subjects: 0
Study: 30460774

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) comprising 15 single-nucleotide polymorphisms
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 920
Study: 30460857

Group type: EXPERIMENTAL
Intervention: Pinhole glasses
Number of subjects: 32
Study: 30461016

Group type: EXPERIMENTAL
Intervention: Keratinized mucosa (KM) band <2 mm
Number of subjects: 37

Group type: COMPARATOR
Intervention: Keratinized mucosa (KM) band ≥2 mm
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Presence of peri-implantitis
Number of subjects: 37
Study: 30461161

Group type: EXPERIMENTAL
Intervention: Caesarean section rates in 2007
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Caesarean section rates in 2013
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Multipara whose labour was not induced or augmented in 2013
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Nullipara whose labour was not induced or augmented
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Multiple pregnancies in 2007
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Multiple pregnancies in 2013
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Overall neonatal mortality in 2007
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Overall neonatal mortality in 2013
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Neonatal mortality in multiparous women whose labour was not induced or augmented in 2007
Number of subjects: 34063

Group type: EXPERIMENTAL
Intervention: Neonatal mortality in multiparous women whose labour was not induced or augmented in 2013
Number of subjects: 34063
Study: 30461442

Group type: EXPERIMENTAL
Intervention: Cigarettes (number of cigarettes/day)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Nonmedical prescription stimulants (NPS) (days of NPS use)
Number of subjects: 498
Study: 30461441

Group type: EXPERIMENTAL
Intervention: Participants' perceptions about drug use behaviors among US adults
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Normative beliefs about contemporaneous patients in the heroin withdrawal program
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Normative perceptions
Number of subjects: 241
Study: 30461641

Group type: EXPERIMENTAL
Intervention: ABSI (A body shape index)
Number of subjects: 2354
Study: 30462243

Group type: EXPERIMENTAL
Intervention: Higher outdoor temperature
Number of subjects: 222511

Group type: EXPERIMENTAL
Intervention: Relative humidity
Number of subjects: 222511

Group type: EXPERIMENTAL
Intervention: Diuretic-induced hyponatremia
Number of subjects: 222511
Study: 30462244

Group type: EXPERIMENTAL
Intervention: Creatinine-adjusted urinary concentrations of mono-2-ethylhexyl phthalate (MEHP)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Creatinine-adjusted urinary concentrations of mono-2-ethyl-5-oxohexyl phthalate (MEOHP)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Creatinine-adjusted urinary concentrations of mono-2-ethyl-5-hydroxyhexyl phthalate
Number of subjects: 209
Study: 30462688

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) patients
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Self-distraction coping
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Internalized HIV/AIDS stigma
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Instrumental support
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Behavioral disengagement coping
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Instrumental support by income
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Partner status by age
Number of subjects: 362
Study: 30463526

Group type: EXPERIMENTAL
Intervention: High OSA risk (41% of patients)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Severe insomnia symptoms (27% of patients)
Number of subjects: 190
Study: 30463565

Group type: EXPERIMENTAL
Intervention: Dobutamine cardiovascular magnetic resonance (CMR) stress testing
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Myocardial ischemia during dobutamine CMR testing
Number of subjects: 327
Study: 30463844

Group type: EXPERIMENTAL
Intervention: Substitution studies (energy matched comparisons with other macronutrients)
Number of subjects: 5086

Group type: EXPERIMENTAL
Intervention: Addition studies (excess energy from sugars added to diets)
Number of subjects: 5086

Group type: EXPERIMENTAL
Intervention: Ad libitum studies (sugars freely replaced by other macronutrients without control for energy)
Number of subjects: 5086

Group type: EXPERIMENTAL
Intervention: Substitution studies
Number of subjects: 5086
Study: 30463996

Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 0
Study: 30464579

Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg/day
Number of subjects: 353

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 353
Study: 30465166

Group type: EXPERIMENTAL
Intervention: C4B copy number
Number of subjects: 145
Study: 30465184

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 797
Study: 30465321

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study: 30465637

Group type: EXPERIMENTAL
Intervention: CI532 slim modiolar electrode
Number of subjects: 44
Study: 30466205

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) administered in the morning for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) administered at mid-day for 10 weeks with dose escalation at 7.5, 10, 15, 30, and 45 minutes/day.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo for 1 week prior to randomization.
Number of subjects: 3
Study: 30466410

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice/day)
Number of subjects: 1
Study: 30466435

Group type: EXPERIMENTAL
Intervention: Early dieters (first dieted by age 11y)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Dieting behaviors (general)
Number of subjects: 139
Study: 30466832

Group type: EXPERIMENTAL
Intervention: Evolut R self-expanding transcatheter heart valve (THV)
Number of subjects: 1040
Study: 30467013

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) therapy initiated, monitored for biliary concentrations during the first 7 days.
Number of subjects: 41
Study: 30467088

Group type: EXPERIMENTAL
Intervention: Routine opt-out testing for hepatitis C virus
Number of subjects: 24567

Group type: COMPARATOR
Intervention: Risk-based and one-time testing for individuals born between 1945 and 1965
Number of subjects: 24567

Group type: EXPERIMENTAL
Intervention: Chronic infection among those tested positive
Number of subjects: 24567

Group type: EXPERIMENTAL
Intervention: Liver fibrosis assessment
Number of subjects: 24567
Study: 30467135

Group type: EXPERIMENTAL
Intervention: Fesoterodine, administered over a treatment phase of 12 weeks (three cycles of 4 weeks each).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised questionnaires (AD symptoms and quality of life) and bladder and bowel diaries at the end of each treatment cycle.
Number of subjects: 0
Study: 30467461

Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30467660

Group type: EXPERIMENTAL
Intervention: Targeted intra-operative radiotherapy (IORT) with low-energy X-ray plus whole breast irradiation (WBI)
Number of subjects: 215
Study: 30467678

Group type: EXPERIMENTAL
Intervention: Psychological morbidity prediction instrument at ICU discharge
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Traumatic memories
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Lack of social support
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Prediction instrument
Number of subjects: 572
Study: 30467809

Group type: EXPERIMENTAL
Intervention: 3 mL methoxyflurane (self-administered via inhalation under supervision)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard of Care (SoC) including IV morphine for severe pain (NRS ≥ 7); IV paracetamol or ketoprofen for moderate pain (NRS 4-6)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Healthcare professional-rated practicality of study treatment at 30 min after randomisation using a 5-point Likert scale
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Methoxyflurane and SoC
Number of subjects: 272
Study: 30468137

Group type: EXPERIMENTAL
Intervention: TRD group
Number of subjects: 1148

Group type: COMPARATOR
Intervention: TRD versus responders
Number of subjects: 1148

Group type: COMPARATOR
Intervention: TRD versus responders and non-responders
Number of subjects: 1148
Study: 30468243

Group type: EXPERIMENTAL
Intervention: PI3Kα inhibition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PI3K-targeted drugs
Number of subjects: 80
Study: 30470143

Group type: EXPERIMENTAL
Intervention: Patients in bout (n=17)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Patients in remission (n=11)
Number of subjects: 43
Study: 30470502

Group type: EXPERIMENTAL
Intervention: Systematic biopsy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Targeted biopsy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both techniques (systematic and targeted biopsy)
Number of subjects: 251
Study: 30470569

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral drugs for chronic hepatitis C
Number of subjects: 0
Study: 30470580

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg BID
Number of subjects: 318
Study: 30470662

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard treatment not specified)
Number of subjects: 0
Study: 30471304

Group type: EXPERIMENTAL
Intervention: Recombinant hypoallergenic fragments of birch pollen allergen Bet v 1
Number of subjects: 0
Study: 30471345

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ICG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ICG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3 mg/kg ICG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg/kg ICG
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg/kg ICG
Number of subjects: 45
Study: 30471555

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC) containing red yeast rice and berberine
Number of subjects: 30

Group type: COMPARATOR
Intervention: No active treatment (noNC)
Number of subjects: 30
Study: 30471649

Group type: EXPERIMENTAL
Intervention: Lenvatinib (E7080)
Number of subjects: 0
Study: 30471652

Group type: EXPERIMENTAL
Intervention: Ixazomib-cyclophosphamide-dexamethasone (ICd) followed by ixazomib maintenance; 4.0 mg of ixazomib, 300 mg (Arm A) or 400 mg (Arm B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance
Number of subjects: 70
Study: 30471965

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over ipsilesional primary motor cortex
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over contralesional primary motor cortex
Number of subjects: 7
Study: 30472259

Group type: EXPERIMENTAL
Intervention: High PALB2 mRNA expression
Number of subjects: 177
Study: 30472317

Group type: EXPERIMENTAL
Intervention: High pretherapy psychoneurological symptoms (n = 51; 16%)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Low pretherapy psychoneurological symptoms (n = 268; 84%)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Matched noncancer controls (n = 347)
Number of subjects: 666
Study: 30472553

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol) 100,000 IU bolus dose followed by 20,000 IU per week
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 30472651

Group type: EXPERIMENTAL
Intervention: ld-IL2 (1 million IU/day for 5 days, followed by fortnightly injections for 6 months)
Number of subjects: 46
Study: 30472660

Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring with antiepileptic drugs (AEDs)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Continuous EEG monitoring without antiepileptic drugs (AEDs)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring
Number of subjects: 214
Study: 30472975

Group type: EXPERIMENTAL
Intervention: Healthy Purchase Index (HPI)
Number of subjects: 112
Study: 30473706

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin or oxaliplatin
Number of subjects: 71
Study: 30473794

Group type: EXPERIMENTAL
Intervention: AT gamma (36 IU/kg/day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: pAT (30 IU/kg/day)
Number of subjects: 222
Study: 30474567

Group type: EXPERIMENTAL
Intervention: Idalopirdine (10, 30, or 60 mg/day)
Number of subjects: 2506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2506
Study: 30474818

Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec/insulin aspart) administered twice daily (BID)
Number of subjects: 2

Group type: COMPARATOR
Intervention: BIAsp 30 administered twice daily (BID)
Number of subjects: 2
Study: 30475172

Group type: EXPERIMENTAL
Intervention: FES rowing exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30475331

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prone positioning with PLR+
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prone positioning with PLR-
Number of subjects: 26
Study: 30475947

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Number of subjects: 84
Study: 30475950

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Number of subjects: 170
Study: 30475958

Group type: EXPERIMENTAL
Intervention: Fetal FADS genotypes
Number of subjects: 390
Study: 30475970

Group type: EXPERIMENTAL
Intervention: Serum retinyl esters (REs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Total serum VA as REs >7.5%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Serum retinol sensitivity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hepatic α-retinol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Histologic indicators of toxicity
Number of subjects: 27
Study: 30475972

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Fish intake by 2 servings/wk
Number of subjects: 351